bioAffinity Technologies to Present at the 8th Annual Dawson James Small Cap Growth Conference
10 October 2023 - 11:00PM
Business Wire
CEO Maria Zannes to hold one-on-one investor
meetings and present a corporate update highlighting commercial
strategy
bioAffinity Technologies, Inc. (Nasdaq: BIAF;
BIAFW), a biotechnology company addressing the need for
noninvasive detection of early-stage lung cancer, today announced
that Maria Zannes, President and CEO, will be participating in the
8th Annual Dawson James Small Cap Growth Conference being held on
Thursday, Oct. 12, 2023, in Jupiter, Florida.
Ms. Zannes is scheduled to present a company overview at 9:30
a.m. ET in Track One-Preserve Ballroom C at the Wyndham Grand
Jupiter at Harbourside Place. She will also be holding one-on-one
meetings with prospective investors throughout the day.
On September 19, bioAffinity Technologies announced the
acquisition of the clinical laboratory that helped develop and
licensed CyPath® Lung, a noninvasive test for the early detection
of lung cancer currently available as a laboratory developed test
(LTD). The acquired laboratory assets are now known as Precision
Pathology Laboratory Services, LLC.
“Our in-depth marketing research for CyPath® Lung has shown that
physicians are enthusiastic about using our test. Our market
research has equipped us with a well-documented commercial growth
strategy that I look forward to sharing at the Dawson James
conference,” Ms. Zannes said. “Our recent acquisition of Precision
Pathology Laboratory Services strengthens our commercial potential
with a large and growing base of physician customers. The
acquisition also boosts our R&D capabilities for additional
tests under development. We believe bioAffinity will be able to
build on the success of CyPath® Lung to become a leader in
diagnostics.”
Event:
8th Annual Dawson James Small Cap Growth
Conference
Date:
Thursday, October 12, 2023
Time:
9:30 a.m. Eastern Time
Location:
Track One-Preserve Ballroom C, Wyndham
Grand Jupiter at Harbourside Place
Webcast:
https://wsw.com/webcast/dawson8/biaf/1990152
A webcast of the presentation will be live and archived on the
News & Events section of the company website.
About Dawson James Securities, Inc.
Dawson James Securities specializes in capital raising for small
and microcap public and private growth companies primarily in the
Life Science/Health Care, Technology, Clean Tech and Consumer
sectors. We are a full-service investment banking firm with
research, institutional and retail sales, and execution trading and
corporate services. By investing the time required to completely
understand your business, we can provide an appropriate capital
transaction structure and strategy including direct investment
through our independent fund. Our team will assist in crafting your
vision and shaping your message for the capital markets.
Headquartered in Boca Raton, Florida, Dawson James is privately
held with offices in New York, Maryland and New Jersey.
www.dawsonjames.com
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. addresses the need for
noninvasive diagnosis of early-stage cancer and diseases of the
lung, and targeted cancer treatment. The Company’s first product,
CyPath® Lung, is a noninvasive test that has shown high sensitivity
and specificity for the detection of early-stage lung cancer.
OncoSelect® Therapeutics, LLC, a subsidiary of bioAffinity
Technologies, is advancing its discoveries shown in vitro to kill
cancer cells without harm to normal cells. Research and
optimization of the Company’s platform technologies are conducted
in its laboratories at The University of Texas at San Antonio. For
more information, visit www.bioaffinitytech.com.
Forward-Looking Statements
This press release contains certain forward-looking statements
within the meaning of the safe harbor provisions of the Private
Securities Litigation Reform Act of 1995. These statements are
identified by the use of the words "could," "believe,"
"anticipate," "intend," "estimate," "expect," "may," "continue,"
"predict," "potential," "project" and similar expressions that are
intended to identify forward-looking statements and include
statements regarding bioAffinity being able to build on the success
of CyPath® Lung to become a leader in diagnostics. These
forward-looking statements are based on management's expectations
and assumptions as of the date of this press release and are
subject to a number of risks and uncertainties, many of which are
difficult to predict, that could cause actual results to differ
materially from current expectations and assumptions from those set
forth or implied by any forward-looking statements. Important
factors that could cause actual results to differ materially from
current expectations include, among others, the Company’s ability
to successfully integrate the pathology laboratory acquisition and
increase revenue, the Company’s ability to pursue the development
and support the commercialization of its CyPath® Lung test, the
Company’s ability to build near and longer-term value for its
Company’s shareholders and the risk factors described in the
Company's Annual Report on Form 10-K for the year ended December
31, 2022, the Company's Quarterly Reports on Form 10-Q, the
Company's Current Reports on Form 8-K and subsequent filings filed
with the Securities and Exchange Commission. The information in
this release is provided only as of the date of this release, and
the Company undertakes no obligation to update or revise publicly
any forward-looking statements, whether as a result of new
information, future events or otherwise, after the date on which
the statements are made or to reflect the occurrence of
unanticipated events, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20231010755952/en/
bioAffinity Technologies Julie Anne Overton Director of
Communications jao@bioaffinitytech.com
LHA Investor Relations Tirth T. Patel tpatel@lhai.com
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Aug 2024 to Sep 2024
bioAffinity Technologies (NASDAQ:BIAFW)
Historical Stock Chart
From Sep 2023 to Sep 2024